Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.
Trevi Therapeutics has raised $173.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Trevi Therapeutics's investors include Vivo Capital, Adage Capital Management, New Enterprise Associates, Omega Funds, Frazier Life Sciences.
Trevi Therapeutics is headquartered in Sandy Hook, United States.
Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.
Trevi Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trevi Therapeutics — Funding & Investors." VCBacked, April 16, 2026, https://www.vcbacked.co/company/trevi-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Trevi Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/trevi-therapeutics
{{cite web |title=Trevi Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/trevi-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated